Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Trial Profile

Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Trebananib (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Ovarian cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 31 May 2019 Results (n=15) assessing the tolerability of pembrolizumab and trebananib in patients with colorectal cancer, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
    • 31 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 07 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top